Featured Insights
-
Boosting Quality And Reducing Complexity With A Single-Provider PV Solution
4/17/2026
Discover how a German biopharmaceutical company successfully managed growing global pharmacovigilance complexity across more than 2,300 marketing authorizations and a broad partner network.
-
Inside The Payer Perspective On Cell And Gene Therapy Coverage
3/2/2026
Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ
1/6/2025
The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
-
Cell And Gene Therapy Commercialization Handbook
11/24/2025
Bringing advanced therapeutics to market requires overcoming hurdles in regulation, logistics, and reimbursement. Learn how to coordinate supply chains and implement adaptive strategies for long-term commercial success.
-
Partnering With Health Systems: Essential Tips For CGT Commercialization
12/5/2025
Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
-
Navigating The CGT Supply Chain: Key Logistical Challenges And Solutions
7/16/2025
Commercializing cell and gene therapies requires overcoming complex logistical hurdles. Customized strategies for temperature control, compliance, and end-to-end delivery are crucial to prevent supply chain issues.
-
Understanding The EU Regulatory Landscape For Cell And Gene Therapies
4/9/2026
EU approval for cell and gene therapies isn't just a different process, it's a different playbook. Here's what US manufacturers need to know before they engage.
-
Specialist PV Support Transforms Safety For Orphan Medicinal Products
4/17/2026
Learn how a UK-based company developing two orphan-designated, centrally authorized therapies successfully navigated operational challenges after transitioning from a prior provider.
-
Transforming PSP Enrollment To Enhance User Experiences And Optimize Workflows
2/18/2026
Lengthy enrollment calls burden patients and PSP teams alike. See how a digital-first intake approach cut onboarding time and improved outcomes for everyone involved.
-
Unraveling The Complexity Of Cell Therapy: Advancements And Challenges
11/26/2024
Cell therapy has emerged as a powerful tool for addressing critical medical challenges, but its rapid evolution necessitates a clear regulatory framework and consistent terminology.